- This event has passed.
BioBusiness Insights: Achieving Functional Efficacy
November 26, 2020 @ 9:00 am - 10:30 am AEDT
Event Navigation
This is Session 3 in the BioBusiness Insights: Fundamentals of Corporate Governance series. Find out more about Session 1 and Session 2, and select a Full Series ticket below for a discounted rate.
- Are you an executive with strategic intent to develop, or re-structure, an effective and functional Board for your organisation?
- Are you seeking to deepen your knowledge and understanding of corporate governance processes?
- Are you considering your own personal pursuit towards directorship?
BioMelbourne Network’s Fundamentals of Corporate Governance program will provide early-stage companies, and career professionals on their path to directorship, with important insights on best practice for developing, managing, and maintaining Board efficiency.
The program, delivered across three unique workshops, will explore the role of the Board; practical strategies and ethical considerations for structuring and improving a Board; the importance of culture in achieving strong governance; key drivers for functional efficacy and; areas of risk and complexity that exist in corporate frameworks.
Informative presentations will be delivered, as well as case studies from industry executives, providing a unique opportunity to hear from leading industry experts and learn from the successes and challenges of others.
Session 3: Achieving Functional Effectiveness will cover:
3.1. Developing an Effective Board – Jo Avasti, EY
- Achieving effectiveness and improved performance
3.2. Drivers for Effectiveness – John Harte, Integrity Governance
- How to make a good Board great
- Managing adversity – conflicts of interest and dysfunctional Chairs/Directors
3.3. Case Studies from Industry Executives – Dr Tim Oldham, AdAlta Ltd & Dr Evelyn Chan, Smileyscope
- Lessons learnt
- Panel discussion and Q&A
Event details for Session 3
Date: Thursday 26 November 2020
Time: 9:00 – 10:30 am AEDT
Tickets: Single session: BioMelbourne Network and Life Sciences Queensland* Members AUD$35; Non-members AUD$45
Full series (three sessions): BioMelbourne Network and Life Sciences Queensland* Members AUD$75; Non-members AUD$105
Unsure if your organisation is a BioMelbourne Network member? Check our member directory.
Find out more about the series (available on demand via series registration): Session 1: Fundamentals of Corporate Governance and Session 2: Building a Competent Board
Speakers
Jo Avasti, Partner, People Advisory Services, EY
John Harte, Managing Partner, Integrity Governance
Dr Tim Oldham, Chief Executive Officer and Managing Director, AdAlta Ltd
Dr Evelyn Chan, Chief Executive Officer, Smileyscope
Read more about our speakers below.
Thanks to our Sponsor for this series, the State Government of Victoria.
*We are pleased to offer Life Sciences Queensland (LSQ) Members a discounted ticket price for this event. Please select “LSQ Member” ticket options below, and when prompted to select your Member Organisation, please select “Non-Member”.
Cancellation Policy:
Full refund given up to 3 days prior to the event.
No refunds within 3 days of the event.
Jo Avasti, Partner, People Advisory Services, EY
Joanne is a Partner in EY’s People Advisory Services practice in Australia and leads our Executive Remuneration practice in Oceania.
Her areas of expertise include developing remuneration strategy aligned to corporate performance, effective stakeholder engagement and governance.
Joanne works with Board Remuneration Committees and executive teams of large national and international organisations, predominantly ASX 100. Prior to moving to Australia in 2004, Joanne worked in the UK, advising FTSE100 companies.
Joanne holds both a Bachelor of Science majoring in business and law, as well as a Master of Science (Research) in law from Aston University (UK). She is a member of the Chartered Institute of Taxation (UK).
Her areas of expertise include developing remuneration strategy aligned to corporate performance, effective stakeholder engagement and governance.
Joanne works with Board Remuneration Committees and executive teams of large national and international organisations, predominantly ASX 100. Prior to moving to Australia in 2004, Joanne worked in the UK, advising FTSE100 companies.
Joanne holds both a Bachelor of Science majoring in business and law, as well as a Master of Science (Research) in law from Aston University (UK). She is a member of the Chartered Institute of Taxation (UK).
John Harte, Managing Partner, Integrity Governance
John is the Managing Partner of Integrity Governance. He specialises in working with businesses at a point of inflection, and boards and businesses under pressure due to change.
Prior to establishing Integrity Governance over 16 years ago, John worked across a range of industries and held chief executive, chairman and director roles in a number of companies around the world. John’s extensive experience means he’s equipped to help you navigate growth, new markets, mergers, acquisitions and crises; and the pressures of new ownership, generational, economic or legislative forces.
John is a core international facilitator for the Australian Institute of Company Directors, and is an in-demand speaker and thought leader on board effectiveness, practical governance and business disruption. He’s a Fellow of the Australian Institute of Company Directors, the Institute of Directors (UK), a Board Leadership Fellow of the National Association of Corporate Directors (USA) and a member of the Chartered Institute of Public Relations. Originally trained as a veterinarian, John works with emerging and mature biotech businesses around the world combining knowledge of science, regulation and governance in a practical way.
Prior to establishing Integrity Governance over 16 years ago, John worked across a range of industries and held chief executive, chairman and director roles in a number of companies around the world. John’s extensive experience means he’s equipped to help you navigate growth, new markets, mergers, acquisitions and crises; and the pressures of new ownership, generational, economic or legislative forces.
John is a core international facilitator for the Australian Institute of Company Directors, and is an in-demand speaker and thought leader on board effectiveness, practical governance and business disruption. He’s a Fellow of the Australian Institute of Company Directors, the Institute of Directors (UK), a Board Leadership Fellow of the National Association of Corporate Directors (USA) and a member of the Chartered Institute of Public Relations. Originally trained as a veterinarian, John works with emerging and mature biotech businesses around the world combining knowledge of science, regulation and governance in a practical way.
Dr Tim Oldham, Chief Executive Officer and Managing Director, AdAlta Ltd
Tim has almost 20 years of life sciences business development, alliance management, portfolio and product development, and commercialisation experience in Europe, Asia and Australia, with a particular focus on biologics, cell and gene therapies and pharmaceutical products.
Tim was appointed CEO and MD of AdAlta Ltd (ASX:1AD) in October 2019. Immediately prior to this, he was Executive Leader of Tijan Ventures, an advisory business focussed on growing life sciences companies through strategic advisory and interim CEO, executive and non-executive leadership services, with a particular focus on biologics, cell and gene therapies and immunotherapy.
Previous roles include CEO and MD of Cell Therapies Pty Ltd, a leading contract manufacturer and distributor cellular therapies in Asia Pacific, President of Asia Pacific for Hospira, Inc., and a variety of senior management roles with Mayne Pharma Ltd prior to its acquisition by Hospira. Prior to this, Tim was an engagement manager with McKinsey & Co.
Industry and board leadership roles include currently serving as a Non-executive Director at Acrux Ltd (ASX:ACR) and a Director of BioMelbourne Network Inc. He was previously a Non-executive Director of Respiri Ltd (ASX:RSH, chair of the European Generic Medicines Association Biosimilars and Biotechnology Committee, a Director of the Alliance for Regenerative Medicine and a Director of the Generic Medicines Industry Association.
Tim was appointed CEO and MD of AdAlta Ltd (ASX:1AD) in October 2019. Immediately prior to this, he was Executive Leader of Tijan Ventures, an advisory business focussed on growing life sciences companies through strategic advisory and interim CEO, executive and non-executive leadership services, with a particular focus on biologics, cell and gene therapies and immunotherapy.
Previous roles include CEO and MD of Cell Therapies Pty Ltd, a leading contract manufacturer and distributor cellular therapies in Asia Pacific, President of Asia Pacific for Hospira, Inc., and a variety of senior management roles with Mayne Pharma Ltd prior to its acquisition by Hospira. Prior to this, Tim was an engagement manager with McKinsey & Co.
Industry and board leadership roles include currently serving as a Non-executive Director at Acrux Ltd (ASX:ACR) and a Director of BioMelbourne Network Inc. He was previously a Non-executive Director of Respiri Ltd (ASX:RSH, chair of the European Generic Medicines Association Biosimilars and Biotechnology Committee, a Director of the Alliance for Regenerative Medicine and a Director of the Generic Medicines Industry Association.
Dr Evelyn Chan, Chief Executive Officer, Smileyscope
Dr Evelyn Chan is a pediatrician who is passionate about transforming children’s healthcare.
Dr Evelyn Chan completed her Bachelor of Medicine/Bachelor of Surgery with Honours from Monash University. She then trained and worked in paediatrics at The Royal Children’s Hospital, The Royal Women’s Hospital and Eastern Health in Melbourne. Evelyn received a Rhodes Scholarhip to study medical anthropology and public health at the University of Oxford. She focused her research on effective translation and delivery of healthcare across cultures and geographies.
Dr Chan worked at the Boston Consulting Group, specialising in public sector and healthcare strategy. During this time, she led the Young Leaders Program for at-risk teens, and pro-bono work for Jawun Indigenous Initiative. She’s now a ‘doctorprenuer’, as the CEO and co-founder of Smileyscope. Smileyscope grew out of Evelyn’s own clinical experience.
Smileyscope transforms paediatric needle procedures through patient-centred VR. This decreases patient pain and anxiety, makes it quicker and safer for clinicians. Smileyscope has won national awards in healthcare, design and innovation.
She invites you to share Smileyscope’s vision to make healthcare a better place for all.
Dr Evelyn Chan completed her Bachelor of Medicine/Bachelor of Surgery with Honours from Monash University. She then trained and worked in paediatrics at The Royal Children’s Hospital, The Royal Women’s Hospital and Eastern Health in Melbourne. Evelyn received a Rhodes Scholarhip to study medical anthropology and public health at the University of Oxford. She focused her research on effective translation and delivery of healthcare across cultures and geographies.
Dr Chan worked at the Boston Consulting Group, specialising in public sector and healthcare strategy. During this time, she led the Young Leaders Program for at-risk teens, and pro-bono work for Jawun Indigenous Initiative. She’s now a ‘doctorprenuer’, as the CEO and co-founder of Smileyscope. Smileyscope grew out of Evelyn’s own clinical experience.
Smileyscope transforms paediatric needle procedures through patient-centred VR. This decreases patient pain and anxiety, makes it quicker and safer for clinicians. Smileyscope has won national awards in healthcare, design and innovation.
She invites you to share Smileyscope’s vision to make healthcare a better place for all.
